NASBA: A novel approach to assess hormonal receptors and ERBB2 status in breast cancer

Clinical Chemistry and Laboratory Medicine

Volumn 44, Issue 1, 2006, Pages 3-12

  Lamy, Pierre Jean ^a   Verjat, Thibault ^b   Paye, Malick ^b   Servanton, Anne Claire ^a   Grenier, Jean ^a   Leissner, Philippe ^b   Mougin, Bruno ^b  

^a Centre Régional de Lutte Contre le Cancer   (France)

^b BioMérieux   (France)

Author keywords

Breast cancer; ERBB2; Hormone receptors; Nucleic acid sequence based amplification (NASBA)

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; HORMONE RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BINDING ASSAY; BIOSTATISTICS; BREAST CANCER; CONTROLLED STUDY; CYTOSOL; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIGAND BINDING; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROTEIN CONTENT; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; STANDARDIZATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HORMONES; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; SELF-SUSTAINED SEQUENCE REPLICATION; TIME FACTORS;

EID: 29444445015     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2006.002     Document Type: Article

References (49)

1. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.
2. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The ERBB2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003;8:307-25.
3. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90: 1361-70.
4. Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 1999;4:71-7.
5. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Clark E, et al. ERBB2/neu testing in breast cancer. Am J Clin Pathol 2003;120:S53-71.
6. Coradini D, Oriana S, Biganzoli E, Marubini E, Boracchi P, Bresciani G, et al. Relationship between steroid receptors (as continuous variables) and response to adjuvant treatments in postmenopausal women with node-positive breast cancer. Int J Biol Markers 1999;14:60-7.
7. Lamy PJ, Pujol P, Thezenas S, Kramar A, Rouanet P, Guilleux F, et al. Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy. Breast Cancer Res Treat 2002;1:65-71.
8. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000;89:111-7.
9. Biesterfeld S, Veuskens U, Schmitz FJ, Amo-Takyi B, Bocking A. Inter-observer reproducibility of immunocytochemical estrogen- and progesterone receptor status assessment in breast cancer. Anticancer Res 1996;16:2497-500.
10. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Anderson E, Bobrow LG, et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol 2001;115:44-58.
11. Poola I, Williams DM, Koduri S, Ramprakash J, Taylor RE, Hankins WD. Quantitation of estrogen receptor mRNA copy numbers in breast cancer cell lines and tumors. Anal Biochem 1998;258:209-15.
12. Fasco MJ. Quantitation of estrogen receptor mRNA and its alternatively spliced mRNAs in breast tumor cells and tissues. Anal Biochem 1997;245:167-78.
13. Tong D, Schneeberger C, Czerwenka K, Schmutzler RK, Speiser P, Kucera E, et al. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer. Clin Cancer Res 1999;5:1497-502.
14. Nagai MA, Marques LA, Yamamoto L, Fujiyama CT, Brentani MM. Estrogen and progesterone receptor mRNA levels in primary breast cancer: association with patient survival and other clinical and tumor features. Int J Cancer 1994;59:351-6.
15. Gotteland M, May E, May-Levin F, Contesso G, Delarue JC, Mouriesse H. Estrogen receptors (ER) in human breast cancer. The significance of a new prognostic factor based on both ER protein and ER mRNA contents. Cancer 1994;74:864-71.
16. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-4.
17. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of ERBB2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-72.
18. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. ERBB2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-904.
19. Yaziji H, Gown AM. Controversies and guidelines in tissue-based ERBB2/neu testing in breast cancer. MLO Med Lab Obs 2002;34:12-6, 20-3.
20. Dittadi R, Zancan M, Perasole A, Gion M. Evaluation of ERBB2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay. Int J Biol Markers 2001;16:255-61.
21. Ferrero-Poüs M, Hacène K, Bouchet C, Le Doussal V, Tubiana-Hulin M, Spyratos F. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res 2000;6:4745-54.
22. el-Ahmady O, el-Salahy E, Mahmoud M, Wahab MA, Eissa S, Khalifa A. Multivariate analysis of bcl-2, apoptosis, P53 and ERBB2/neu in breast cancer: a short-term follow-up. Anticancer Res 2002;22:2493-9.
23. Gaci Z, Bouin-Pineau MH, Gaci M, Daban A, Ingrand P, Metaye T. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors. Int J Oncol 2001;18:793-800.
24. Mrhalova M, Kodet R, Kalinova M, Hilska I. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number. Pathol Res Pract 2003;199:453-61.
25. Pawlowski V, Revillion F, Hebbar M, Hornez L, Peyrat JP. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000;6:4217-25.
26. Bieche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R, et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 1999;45:1148-56.
27. Schlemmer BO, Sorensen BS, Overgaard J, Olsen KE, Gjerdrum LM, Nexo E. Quantitative PCR - new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization. Scand J Clin Lab Invest 2004;64:511-22.
28. Gjerdrum LM, Sorensen BS, Kjeldsen E, Sorensen FB, Nexo E, Hamilton-Dutoit S. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for ERBB2/neu analysis. J Mol Diagn 2004;1:42-51.
29. Konigshoff M, Wilhelm J, Bohle RM, Pingoud A, Hahn M. ERBB2/neu gene copy number quantified by real-time PCR: comparison of gene amplification, heterozygosity, and immunohistochemical status in breast cancer tissue. Clin Chem 2003;2:219-29.
30. Kim YR, Choi JR, Song KS, Chong WH, Lee HD. Evaluation of HER2/neu status by real-time quantitative PCR in breast cancer. Yonsei Med J 2002;3:335-40.
31. Millson A, Suli A, Hartung L, Kunitake S, Bennett A, Nordberg MC, et al. Comparison of two quantitative polymerase chain reaction methods for detecting HER2/ neu amplification. J Mol Diagn 2003;3:184-90.
32. Bofin AM, Ytterhus B, Martin C, O'Leary JJ, Hagmar BM. Detection and quantitation of ERBB2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol 2004;122:110-9.
33. Compton J. Nucleic acid sequence-based amplification. Nature 1991;350:91-2.
34. Deiman B, van Aarle P, Sillekens P. Characteristics and applications of nucleic acid sequence-based amplification (NASBA). Mol Biotechnol 2002;20:163-79.
35. Verjat T, Cerrato E, Jacobs M, Leissner P, Mougin B. Multiparametric duplex real-time NASBA assay for mRNA profiling: application to hormone receptor status in breast cancer tumors. bioTechniques 2004;37:476-81.
36. Lowry OH, Roseborough N, Farr L, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
37. de Baar MP, van Dooren MW, de Rooij E, Bakker M, van Gemen B, Goudsmit J, et al. Single rapid real-time monitored isothermal RNA amplification assay for quantification of human immunodeficiency virus type 1 isolates from groups M, N, and O. J Clin Microbiol 2001;39:1378-84.
38. Polstra AM, Goudsmit J, Cornelissen M. Development of real-time NASBA assays with molecular beacon detection to quantify mRNA coding for HHV-8 lytic and latent genes. BMC Infect Dis 2002;2:1-10.
39. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
40. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-5.
41. Brouillet JP, Dujardin MA, Chalbos D, Rey JM, Grenier J, Lamy PJ, et al. Analysis of the potential contribution of estrogen receptor (ER) β in ER cytosolic assay of breast cancer. Int J Cancer 2001;95:205-8.
42. Chevillard S, Muller A, Levalois C, Laine-Bidron C, Vielh P, Magdelenat H. Reverse transcription-polymerase chain reaction (RT-PCR) assays of estrogen and progesterone receptors in breast cancer. Breast Cancer Res Treat 1996;41:81-9.
43. Lacroix M, Querton G, Hennebert P, Larsimont D, Leclercq G. Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immunocytochemical assay, and northern blot: a comparison. Breast Cancer Res Treat 2001;67:263-71.
44. Ariazi EA, Clark GM, Mertz JE. Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res 2002;62:6510-8.
45. Merkelbach-Bruse S, Wardelmann E, Behrens P, Losen I, Buettner R, Friedrichs N. Current diagnostic methods of ERBB2/neu detection in breast cancer with special regard to real-time PCR. Am J Surg Pathol 2003;12:1565-70.
46. Nathanson DR, Nash GM, Chen B, Gerald W, Paty PB. Detection of ERBB2/neu gene amplification in breast cancer using a novel polymerase chain reaction/ligase detection reaction technique. J Am Coll Surg 2003;3:419-25.
47. Eppenberger-Castori S, Kueng W, Benz C, Caduff R, Varga Z, Bannwart F, et al. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol 2001;3:645-56.
48. Pawlowski V, Revillion F, Hornez L, Peyrat JP. A real-time one-step reverse transcriptase-polymerase chain reaction method to quantify c-erbB-2 expression in human breast cancer. Cancer Detect Prev 2000;24:212-23.
49. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:2714-21.